$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414047741 Filed on August 07, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$2.396M	$2.425M	$2.264M
YoY Change	4.9%	7.11%	-91.33%
Cost Of Revenue	$1.798M	$1.605M	$1.318M
YoY Change	13.3%	21.78%	-59.8%
Gross Profit	$1.909M	$1.081M	$1.746M
YoY Change	7.73%	-38.09%	-92.06%
Gross Profit Margin	79.67%	44.58%	77.12%
Selling, General & Admin	$2.012M	$1.566M	$2.182M
YoY Change	13.03%	-28.23%	-37.66%
% of Gross Profit	105.4%	144.87%	124.97%
Research & Development	$8.052M	$7.076M	$7.990M
YoY Change	4.26%	-11.44%	-24.22%
% of Gross Profit	421.79%	654.58%	457.62%
Depreciation & Amortization	$790.0K	$800.0K	$890.0K
YoY Change	-9.2%	-10.11%	-4.3%
% of Gross Profit	41.38%	74.01%	50.97%
Operating Expenses	$10.06M	$8.642M	$10.17M
YoY Change	5.9%	-15.04%	-3.53%
Operating Profit	-$6.208M	-$5.447M	-$6.894M
YoY Change	9.97%	-20.99%	-171.66%
Interest Expense	-$1.800M	-$670.0K	$60.00K
YoY Change	-1612.61%	-1216.67%	200.0%
% of Operating Profit
Other Income/Expense, Net	-$1.802M	-$672.0K	$57.00K
YoY Change	1666.67%	-1278.95%	159.09%
Pretax Income	-$8.010M	-$6.120M	-$6.840M
YoY Change	39.3%	-10.53%	-170.95%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.010M	-$6.119M	-$6.837M
YoY Change	39.38%	-10.5%	-170.91%
Net Earnings / Revenue	-334.31%	-252.33%	-301.99%
Basic Earnings Per Share			-$0.07
Diluted Earnings Per Share	-$0.86	-$0.66	-$0.07
COMMON SHARES
Basic Shares Outstanding	93.66M shares	93.61M shares	92.30M shares
Diluted Shares Outstanding			92.30M shares

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.30M	$71.10M	$33.10M
YoY Change	-34.03%	114.8%	-44.18%
Cash & Equivalents	$60.32M	$71.14M	$33.13M
Short-Term Investments
Other Short-Term Assets	$2.100M	$2.000M	$3.600M
YoY Change	-50.0%	-44.44%
Inventory	$6.830M	$7.135M	$7.191M
Prepaid Expenses
Receivables	$1.992M	$2.097M	$2.030M
Other Receivables	$2.069M	$1.988M	$3.585M
Total Short-Term Assets	$71.21M	$82.36M	$45.93M
YoY Change	-32.31%	79.32%	-30.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.85M	$12.44M	$15.00M
YoY Change	-17.39%	-17.09%	-13.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.700M	$1.800M	$1.400M
YoY Change	6.25%	28.57%	27.27%
Total Long-Term Assets	$13.59M	$14.29M	$16.37M
YoY Change	-14.85%	-12.75%	-11.08%
TOTAL ASSETS
Total Short-Term Assets	$71.21M	$82.36M	$45.93M
Total Long-Term Assets	$13.59M	$14.29M	$16.37M
Total Assets	$84.80M	$96.65M	$62.31M
YoY Change	-30.01%	55.12%	-26.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.600M	$3.600M	$3.900M
YoY Change	9.09%	-7.69%	-13.33%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.38M	$27.18M	$26.63M
YoY Change	-3.34%	2.07%	24.83%
LONG-TERM LIABILITIES
Long-Term Debt			$376.0K
YoY Change			-91.97%
Other Long-Term Liabilities	$40.70M	$42.00M	$47.70M
YoY Change	-10.94%	-11.95%	-13.43%
Total Long-Term Liabilities	$108.1M	$109.3M	$47.66M
YoY Change	-4.02%	129.23%	-13.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.38M	$27.18M	$26.63M
Total Long-Term Liabilities	$108.1M	$109.3M	$47.66M
Total Liabilities	$132.5M	$136.4M	$74.29M
YoY Change	-3.9%	83.66%	-2.81%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$47.69M	-$39.79M	-$11.99M
YoY Change
Total Liabilities & Shareholders Equity	$84.80M	$96.65M	$62.31M
YoY Change	-30.01%	55.12%	-26.09%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$8.010M	-$6.119M	-$6.837M
YoY Change	39.38%	-10.5%	-170.91%
Depreciation, Depletion And Amortization	$790.0K	$800.0K	$890.0K
YoY Change	-9.2%	-10.11%	-4.3%
Cash From Operating Activities	-$9.550M	-$6.520M	-$8.110M
YoY Change	16.32%	-19.61%	-161.81%
INVESTING ACTIVITIES
Capital Expenditures	$250.0K	$110.0K	$700.0K
YoY Change	-24.24%	-84.29%	191.67%
Acquisitions
YoY Change
Other Investing Activities	-$30.00K	-$80.00K	-$20.00K
YoY Change	-66.67%	300.0%
Cash From Investing Activities	-$260.0K	-$200.0K	-$720.0K
YoY Change	-38.1%	-72.22%	200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	0.000	30.00K
YoY Change	-99.99%	-100.0%	-96.97%
NET CHANGE
Cash From Operating Activities	-9.550M	-6.520M	-8.110M
Cash From Investing Activities	-260.0K	-200.0K	-720.0K
Cash From Financing Activities	10.00K	0.000	30.00K
Net Change In Cash	-9.800M	-6.720M	-8.800M
YoY Change	-116.81%	-23.64%	-163.45%
FREE CASH FLOW
Cash From Operating Activities	-$9.550M	-$6.520M	-$8.110M
Capital Expenditures	$250.0K	$110.0K	$700.0K
Free Cash Flow	-$9.800M	-$6.630M	-$8.810M
YoY Change	14.75%	-24.74%	-168.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3152000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	180000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13464000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11158000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	577000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2499000	USD
	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	1628000	USD
	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	1818000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	133000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	120000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	102000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	93000	USD
	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	25000	USD
	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	14000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4369000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4207000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	397000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	406000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-822000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3048000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14859000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17695000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	371000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1341000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	93000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	101000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	71000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-565000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1412000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	31000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	139000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	168000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15254000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18909000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86398000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52035000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71144000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33126000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	170000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	304000	USD
	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	12000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	30000	USD
	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
CY2014Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	70200000	USD
	dei	Trading Symbol TradingSymbol	PLX
CY2014Q2	us-gaap	Inventory Net InventoryNet	7135000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	7957000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	82364000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	97903000	USD
CY2014Q2	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1721000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1578000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12438000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13711000	USD
CY2014Q2	us-gaap	Deferred Costs DeferredCosts	128000	USD
CY2013Q4	us-gaap	Deferred Costs DeferredCosts	141000	USD
CY2014Q2	us-gaap	Assets Assets	96651000	USD
CY2013Q4	us-gaap	Assets Assets	113333000	USD
CY2014Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3592000	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5254000	USD
CY2014Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	16305000	USD
CY2013Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	12073000	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7282000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9369000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	27179000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26696000	USD
CY2014Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67255000	USD
CY2013Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67048000	USD
CY2014Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	39514000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	41796000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2371000	USD
CY2014Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2493000	USD
CY2013Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2368000	USD
CY2014Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	109262000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	113583000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	136441000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	140279000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	-39790000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-26946000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96651000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113333000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2097000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2091000	USD
CY2014Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1988000	USD
CY2013Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1457000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		USD
	plx	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
CY2009Q4	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	60000000	USD
	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	3500000	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7413383	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18844777	shares
	us-gaap	Inventory Write Down InventoryWriteDown	1600000	USD
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7356464	shares
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18778154	shares
CY2014Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1845000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2342000	USD
CY2014Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	133000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	92000	USD
CY2014Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5157000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5523000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-3357000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	645000	USD
	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	1854000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	190000	USD
	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	387000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-11986000	USD
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Revenues Revenues	9121000	USD
	us-gaap	Revenues Revenues	5832000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	43000	USD
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	1667	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	plx	Other Gains Losses OtherGainsLosses	948000	USD
	plx	Other Gains Losses OtherGainsLosses	1200000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	5678000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	2289000	USD
	us-gaap	Gross Profit GrossProfit	4391000	USD
	us-gaap	Gross Profit GrossProfit	4743000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15228000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15744000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	4199000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	3963000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	11029000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	11781000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5277000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4285000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11915000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11323000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1789000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	240000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1549000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	165000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92754640	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92241505	shares
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	1605000	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	1318000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	1081000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	1746000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7076000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7990000	USD
CY2014Q2	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	2114000	USD
CY2013Q2	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	1532000	USD
CY2014Q2	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	4962000	USD
CY2013Q2	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	6458000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1566000	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2182000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5447000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6894000	USD
CY2014Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	874000	USD
CY2014Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	202000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-672000	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	57000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-6119000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-6837000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92820897	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92297522	shares
CY2014Q2	us-gaap	Revenues Revenues	2425000	USD
CY2013Q2	us-gaap	Revenues Revenues	2264000	USD
CY2014Q2	plx	Other Gains Losses OtherGainsLosses	261000	USD
CY2013Q2	plx	Other Gains Losses OtherGainsLosses	800000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	187000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	22000	USD
CY2013Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	66000	USD
CY2013Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9000	USD
	dei	Document Type DocumentType	10-Q
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93664898	shares

Files In Submission

Name	View Source	Status
0001144204-14-047741-index-headers.html	Edgar Link	pending
0001144204-14-047741-index.html	Edgar Link	pending
0001144204-14-047741.txt	Edgar Link	pending
0001144204-14-047741-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
plx-20140630.xml	Edgar Link	completed
plx-20140630.xsd	Edgar Link	pending
plx-20140630_cal.xml	Edgar Link	unprocessable
plx-20140630_def.xml	Edgar Link	unprocessable
plx-20140630_lab.xml	Edgar Link	unprocessable
plx-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v384196_10q.htm	Edgar Link	pending
v384196_ex31-1.htm	Edgar Link	pending
v384196_ex31-2.htm	Edgar Link	pending
v384196_ex32-1.htm	Edgar Link	pending
v384196_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2014 Q3 Form 10-Q Financial Statement

#000114420414047741 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2014 Q3 Form 10-Q Financial Statement

#000114420414047741 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx